Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm intrigued by the potential here, but this is definitely one where you buy some shares with money you can afford to lose, set them aside, and see where this ends up in a few years. Or just follow the story and invest later if successful, but at a higher price with less risk.
I suppose that the new was presented and taken as a joke; so humorously 🤡
I don’t think it was insiders. Look at the filings. They converted commons into preferreds and reduced OS by 70mil shares or roughly 1/2.
I bought a few this week and continue to hold a large bag.
Not calling this an out right buy. I found the PR encouraging but lack of movement on that news is troubling me.
If it’s all bs. The bag will get larger. If they are now looking for a partner to invest to bring this thru trials we could easily see .50 All speculation on my part I’m loosing a ton here.
So is the company or the shorts selling since the selling seems sizable enough on a Friday after massive news so who would be selling on life changing news or was that just some bull?
wash rinse repeat
lower highs followed by lower lows
click the price chart/graph over on the right side --try 1 year
If Bioxytrans has patients on such a Glorious claim all Majors must be taken notice: So possibly buyout or takeover would definitely be involved; if not total conniving Suppression Imo
If Bioxytrans has patients on such a Glorious claim all Majors must be taken notice: So possibly buyout or takeover would definitely be involved; if not total conniving Suppression Imo
Interesting the insiders retired commons and exchanged for preferreds just a month ago
What happens next?
$BIXT Major news
https://finance.yahoo.com/news/bioxytrans-medical-breakthrough-fighting-viruses-133500730.html
Bioxytran's Medical Breakthrough in Fighting All Viruses
BioXyTran, Inc.
Thu, September 19, 2024 at 8:35 AM CDT 6 min read
In This Article:
BIXT
+28.37%
Breakthrough was validated in the latest journal article
Galectins are essential for viral entry and a new target for drug development
Carbohydrates were shown to neutralize viruses
Blocking galectins could be the most efficient way to prevent and treat viruses potentially impacting the vaccination and antiviral markets
BOSTON, MA / ACCESSWIRE / September 19, 2024 / BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage biotechnology company developing drugs to treat stroke and Alzheimer's disease, announced a medical breakthrough in virology that was validated in a peer-reviewed medical journal article. The European Society of Medicine published a peer-reviewed article detailing a study which shows how Bioxytran's leading drug candidate, Prolectin-M, stops COVID-19 and other viruses in their tracks. The study used advanced Nuclear Magnetic Resonance (NMR) spectroscopy to reveal how this drug works by blocking a protein called galectin, which helps viruses attach to cells. The discovery could impact both the vaccination and antiviral markets, which combined are estimated at approximately $147 billion according to Grandview Research and Statista.
https://esmed.org/MRA/mra/article/view/5616
The peer-reviewed article identified Galectin-3 as a crucial "glue" that helps the virus attach to and enter human cells by sticking to the ACE2 receptor, altering our existing understanding of how viral infections occur. The discovery was proven using NMR Spectroscopy which is extremely precise compared to the 50-year-old ELISA tests which was used to establish virology's initial foundation on how viruses worked and interacted with antivirals. The report proved that by blocking this process, the drugs prevented the virus from entering the cells, which means the virus couldn't make people sick. The double-blind placebo controlled clinical studies showed that these drugs were 100% effective in reducing symptoms and eliminating the virus in 2 peer-reviewed clinical trials.
The study also pointed out that galectins, located on the spike protein of the virus, are an excellent target for drugs because it doesn't change much, making it easier to stop the virus from attaching to cells. This could make these drugs effective against a wide range of viruses, not just COVID-19.
"This discovery might be one of the most significant advancements in virology," said Dr. David Platt, CEO of Bioxytran. "In our first case study to make a SARS-CoV-2 antiviral drug, it appears we have on our hands the first truly broad-spectrum antiviral that may operate across different families of viruses. We believe we have discovered a reproducible method that could potentially be used to create many antiviral drugs that could potentially quickly fight off new viruses, even those that mutate rapidly. We believe our approach represents a new era in antiviral drug development. With the help of advanced technology and Artificial Intelligence (AI), it is now possible to design antiviral drugs that could potentially neutralize any virus. This discovery could change the way we treat viral diseases and even chronic illnesses like cancer. We believe major advancements in virology with this new tech will be measured in months instead of years and decades as has been the case in the past."
"Using this new platform technology could revolutionize how we create new antiviral treatments," said Dr. Kevin Mayo, Professor of the University of Minnesota.
"Traditional methods of developing antivirals and vaccines are not precise and involve a lot of trial and error. Their weakness has always been their reliance on the immune system to work properly and everyone's immune system is unique.
Our results show we can neutralize viruses without the help of the immunes system making our system incredibly reliable. This breakthrough opens a new chapter in fighting viral diseases, providing hope for treating not only SARS-CoV-2 but other highly pathogenic and contagious viruses influenced by galectins. This may be the crown jewel of virology and a few more tests on other viruses could prove it."
Antiviral and Vaccination Market
The global antiviral drugs market is valued at $72.84 billion according to Grandview Research. The global vaccine market is valued at $74.12 billion in 2024 by Statista. Combined the markets total approximately $147 billion. The growth drivers in antivirals are the increasing prevalence of viral infections like HIV, hepatitis, and influenza, along with the increase in antiviral drug development and treatments. The market is dominated by drugs for HIV, hepatitis C, and influenza, with HIV antivirals holding a substantial market share due to the ongoing need for effective treatments. Additionally, there is a growing demand for broad-spectrum antiviral drugs that can be rapidly deployed in response to emerging viral threats.
The COVID-19 pandemic accelerated vaccine development and distribution. New technological advancements in mRNA technology, protein-based vaccines, and microarray patches are enhancing efficacy, stability and accessibility of vaccines. Growing indications include HPV, pneumococcal infections, and RSV. Global health initiatives to combat malaria and tuberculosis are also driving the development of new vaccines.
About Bioxytran, Inc.
Bioxytran, Inc. is a clinical stage biotechnology company pioneering a library of novel complex carbohydrate structures using artificial intelligence software that interprets the Nuclear Magnetic Resonance imaging of druggable targets like the galectin fold to create a rational drug design. The leading drug candidates vetted by in vitro testing, are capable of neutralizing viruses. The peer-reviewed discovery of the galectin fold located on the spike proteins of viruses such as COVID-19, RSV, and H1N1 demonstrate there exists a conserved region on the spike in which Bioxytran's molecules achieve virus neutralization. The extent of the carbohydrate structure's ability to neutralize untested viruses is unknown just like the initial discovery of antibiotics last century and its ability to treat a broad spectrum of bacterial infections. Applications of this platform technology extend to the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran's other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words "believe," "expect," "anticipate," "estimate," "intend," "plan," and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran's actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
SOURCE: BioXyTran, Inc.
View the original press release
see on accesswire.com
https://www.accesswire.com/920259/bioxytrans-medical-breakthrough-in-fighting-all-viruses
Showed up in E*Trade
WHERE?????????
Yes, but only for the US market.
Still has employees that were part of CYDY fraud scheme in executive positions
Hard to believe anything or anyone as long as it is just pumpers and PR nonsense.
Where are U S real clinical trials?? Where are legit doctors discussing ANY results?? With all this new found money what is the holdup ??
Will the oxygen transport system need to go through an FDA drug approval process? Thanks
$BIXT TA share data was updated, and the OS share count is now down 50%
The Market cap is now down 50% from $14 Million dollars to $7 Million dollars
And they recently scored a HEME-Foundation 10 Million dollar grant (No debt, no share dilution deal)
to fund completion of the $BIXT synthetic oxygen carrier, that has a 5 year shelf life,
and that can be added to blood plasma in emergencies (when there is no time to do tests and blood type tests, and seconds
can me life or death), to ensure the organs, heart and brain get plenty of oxygen.
The $BIXT synthetic oxygen carrier molecule is so small
it can easily by pass blood clots, while hemoglobin is too large to get past the blood clots.
It will be a game changing life saver in operating rooms, emergency rooms and mash casualty disaster events.
All on top of the having the worlds only Galectin inhibitor that is a non-toxic oral pill, that can stop 60+ viruses from infected human cells, and has world wide PCT patent coverage, and has phase III US FDA IND drug trial approval for long haul Covid, has been tested as a skin cream that stops shingles sores, and is ready for a phase III Covid trial in India.
http://www.bixytaninc.com
NEW BIXT snippet -
Wow........that's pretty amazing Mike!!........$BIXT will be one of the Big Boys one day............
Z
How many companies do we know besides $BIXT that can raise 10 million dollars with out using shares or debt to move towards completing just one of their major new medical miracles?
NEW BIXT snippet -
Great info thx , still in research mode
100%. You were warned
No wonder this traded down 30% at one point today.
Folks When EGOmike™ is Pumping You better be Dumping.
No one pumps on more No bid stock boards than the EGO.
He has pumped on more.000001 boards than you can shake a stick at.
The BIXT I-Box, info has been created here. Check it out folks
This is not that type of company. It is not a brick and mortar firm, which in many ways are becoming obsolete. It's product development is spread out in several countries
What matters is the people and their credentials. Experience and genius matters.
https://www.bioxytraninc.com/team
Management Team
David Platt
CEO & Chairman
PhD
Dr. Platt is a world-renowned expert in carbohydrate chemistry who has founded three publicly traded companies, creating nearly $1B for investors. He has raised $150M directly in public markets in the U.S., and has led development of two drug candidates from concept through phase II clinical trials. Prior to BioXyTran Inc. Dr. Platt founded Boston Therapeutics Inc. in 2010 (OTC: BTHE). Between 2001 and 2009, Dr. Platt became a founder of Pro-Pharmaceuticals, Inc. (OTC: PRWP and AMEX: PRW, now NASDAQ: GALT), and served as its chief executive officer and board chairman. In 1995 Dr. Platt founded International Gene Group (NASDAQ: IGGI, GLGS now LPJC); he continued to serve the firm through 2000.
Ola Soderquist
CFO
CPA, CMA, CM&AA
Mr. Soderquist has more than 30 years of senior international entrepreneurial management experience within technology companies. He has served in CFO and other managerial capacities in multiple industry sectors and companies, such as Industrivarden (OMX:INDU), Electrolux (OMX:ELUX), Ericsson (NASDAQ:ERIC), Swedish Match (OMX:SWMA) and SKF AB (OMX:SKF), and most recently in Belden (NYSE: BDC) and Traction (OMX:TRAC). Ola is a multi-lingual senior finance professional poised to work globally and cross-functionally, particularly with complex projects involving business integration, systems implementation, continuous improvement, and process excellence. Ola’s managerial experience portfolio includes; Start-ups, Private, Public, Venture Capital and Private Equity ownership. He obtained a BS and an MS in Accounting from Stockholm School of Economics and an MBA from Babson College – Franklin W. Olin Graduate School of Business.
Dr. Leslie Ajayi
CMO & Medical Advisory Board Chief
MD
Dr. Ajayi brings over 20 years of clinical development experience in academia and industry. He is a fully trained physician leader with international specialty training in internal medicine, cardiovascular medicine, and clinical pharmacology. He received his undergraduate training in Health Sciences and his MD equivalent graduating Magna Cum Lade from Obafemi Awolowo University [OAU] in Nigeria. A few years later he received his PhD in clinical pharmacology from the University of Glasgow. As an academic clinical pharmacologist in Glasgow, UK, he worked with Big Pharma as an investigator for Phase 1 first in man, proof of concept, pharmacokinetics (PK), Pharmacodynamics (PD), PK-PD, and studies in special populations such as the elderly and in pregnancy. He was also involved in all types of designs of randomized controlled clinical trials (double blind, placebo controlled, double dummy, single blind, cross over, parallel group, Latin squares designs). His industry exposure was relegated to big pharma clinical research monitors and clinical research organizations. He worked on notable projects like perindopril and cilazapril (ACEI), and amlodipine. He evaluated the effects of ACEI on Type-2 Diabetes and insulin resistance in hypertensives.
Mike Sheikh
Chief Communication Officier
BS
Mr. Sheikh worked as a Broker and eventually Research Analyst at Dean Witter and National Securities. He is a long-time Biotech Consultant expertise for public or private biotech companies with disruptive technologies. Mr. Sheikh the founder of Falcon Strategic Research. Mike has a BS in Economics and is a US Air Force Academy graduate and pilot.
Board of Directors
David Platt
PHD
CEO & CHAIRMAN OF THE BOARD
Dr. Platt is a world-renowned expert in carbohydrate chemistry who has founded four publicly traded companies, creating nearly $1B for investors. He has raised $150M directly in public markets in the U.S. and has led the development of two drug candidates from concept through phase II clinical trials. Prior to BioXyTran Inc. Dr. Platt founded Boston Therapeutics Inc. in 2010 (OTC: BTHE). Between 2001 and 2009, Dr. Platt became a founder of Pro-Pharmaceuticals, Inc. (OTC: PRWP and AMEX: PRW, now NASDAQ: GALT), and served as its chief executive officer and board chairman. In 1995 Dr. Platt founded the International Gene Group (NASDAQ: IGGI, GLGS now LPJC); he continued to serve the firm through 2000.
Anders N. Utter
Director
Financial Expert
Mr. Utter has more than 25 years of finance, accounting and management experience in medical devices, consulting and manufacturing industries in capacities as CFO, Controller and Managing Director. He had progressively increased management experience in the European Nolato Group and later on in the Amplex Group. Mr. Utter has had a broad business exposure with IFRS and GAAP reporting as well as with SOX compliance. He has also worked with M&A evaluations, financing and integration as well as more hands-on manufacturing cost accounting and reporting. He is currently in charge of the finance control at one of General Cable’s entities. Mr. Utter is and has been serving as a director on boards in both profit as well as non-profit organizations. Mr. Utter holds an MBA from Babson College and a BA from Uppsala University in Sweden.
Alan M. Hoberman
Director
PhD
Alan M. Hoberman, PhD is president and CEO of Argus International, Inc., overseeing a staff of scientists and other professionals who provide consulting services for industry, government agencies, law firms, and other organizations, both in the U.S. and internationally. Between 1991 and 2013 he held a series of positions of increasing responsibility at Charles River Laboratories Preclinical Services (formerly Argus Research Laboratories, Inc.), most recently as Executive Director of Site Operations and Toxicology. He currently works with that organization to design, supervise, and evaluate reproductive and developmental toxicity, neurotoxicity, inhalation, and photobiology studies. Dr. Hoberman holds a PhD in toxicology from Pacific Western University, an MS in interdisciplinary toxicology from the University of Arkansas, and a BS in biology from Drexel University.
Dale H. Conaway
Director
DVM
We are proud to have Dr.Dale H. Conaway as a board member at Bioxytran Inc. From 1998 to 2001, Dr. Conaway served as Manager of the Equine Drug Testing and Animal Disease Surveillance Laboratories for the Michigan Department of Agriculture. From 1994 to 1998, he was Regulatory Affairs Manager for the Michigan Department of Public Health Vaccine Production Division. From May 2001 to February 2009, Dr. Conaway was a director of Pro-Pharmaceuticals, Inc., a public company with shares traded on the NYSE Alternext US. Dr. Conaway received a DVM degree from Tuskegee Institute and an MS degree in pathology from the College of veterinary medicine at Michigan State University.
Advisory Board
Dr. Kevin Mayo
Medical Advisory Board
PHD
Prof. Kevin H Mayo, Ph.D. is a well-known authority in the field of structural biology and structure-based drug design and discovery. He received degrees from Boston University (BA) and the University of Massachusetts (PhD), and was a postdoctoral associate at the Max-Planck Institute for Biochemistry (Alexander von Humboldt Fellow with Nobel Laureate Rudolf Moessbauer) and Yale University (Chemistry). Dr. Mayo is presently Professor of Biochemistry, Molecular Biology & Biophysics, as well as Lab Medicine & Pathology, at the University of Minnesota (UMN), Minneapolis, USA. He is also Director of the High Field Nuclear Magnetic Resonance Center at the UMN. Over the years, Dr. Mayo has consulted with numerous pharmaceutical companies and is co-founder of PepTx, Inc., a startup pharmaceutical company based in Minnesota. He also currently holds Visiting Professorships at Maastricht University (The Netherlands), Ludwigs-Maximillian-University (Munich, Germany), and Northeast Normal University (Changchun, China). Dr. Mayo has published over 250 papers in peer-reviewed scientific journals and is the author of 28 patents.
Dr. Leslie Ajayi
CMO & Medical Advisory Board Chief
MD
Dr. Ajayi brings over 20 years of clinical development experience in academia and industry. He is a fully trained physician leader with international specialty training in internal medicine, cardiovascular medicine, and clinical pharmacology. He received his undergraduate training in Health Sciences and his MD equivalent graduating Magna Cum Lade from Obafemi Awolowo University [OAU] in Nigeria. A few years later he received his PhD in clinical pharmacology from the University of Glasgow. As an academic clinical pharmacologist in Glasgow, UK, he worked with Big Pharma as an investigator for Phase 1 first in man, proof of concept, pharmacokinetics (PK), Pharmacodynamics (PD), PK-PD, and studies in special populations such as the elderly and in pregnancy. He was also involved in all types of designs of randomized controlled clinical trials (double blind, placebo controlled, double dummy, single blind, cross over, parallel group, Latin squares designs). His industry exposure was relegated to big pharma clinical research monitors and clinical research organizations. He worked on notable projects like perindopril and cilazapril (ACEI), and amlodipine. He evaluated the effects of ACEI on Type-2 Diabetes and insulin resistance in hypertensives.
Dr. John Mabayoje
Medical Advisory Board
MD
Dr. Mabayoje is an active practicing Emergency Room doctor and Medical Director who graduated from the University of Ife /OAU in 1980. He has 6 years of residency/ fellowship training in internal medicine, family practice, geriatric medicine, substance abuse, and emergency medicine. He also has 125 hours of sonography training. He is licensed to practice in a number of states and has 44 years’ experience in emergency medicine in the United States and internationally. He has published research work on histochemistry. He has extensive experience with COVID-19 patients treating over 4,800 patients on 2 continents. He is known in circles as an astute diagnostician and innovator looking for ways to getting the best therapeutic advantages for his patients.
Dr. Thomaskutty Alumparambil
Scientific Advisory Board
B.S., C.C.P
Dr. Thomaskutty Alumparambil. B.S., C.C.P has over 30 years of clinical experience that includes heart, lung, and liver transplants. He is an expert on quality control and quality assurance programs, surgical protocols, blood gas analysis and anticoagulation management.
Dr. Alben Sigamani
Scientific Advisory Board
MD
Dr. Alben Sigamani, MD. Dr.Sigamani is currently Professor and Head of Clinical Research, Narayan Health, Bangalore. He has over 17 years of experience in clinical research and in managing multi-center academic and regulatory Randomized Controlled Trials in India. He has several publications to his credit with a citation index (h-index) of 24. Dr. Sigamani is a Medical Professional (MD) in Clinical Pharmacology & Therapeutics with a Masters Degree in Clinical Trials from the University of London. In 2020, Dr. Sigamani obtained “COVID-19: Tracking The Novel Coronavirus Certificate ” from the London School of Hygiene and Tropical Medicine.
Prof. Avraham Mayevsky
Scientific Advisory Board
PhD
Prof. Avraham Mayevsky is a worldwide authority in the field of minimal invasive monitoring of tissue and organ physiology. Prof. Mayevsky is a professor at the Faculty of Life Sciences, Bar-Ilan University, Israel. He founded Vital Medical Ltd. He served as Head of the Department of Life Sciences and Dean of the Faculty of Natural Sciences at Bar-Ilan University, where he established a center of tissue physiology. He served as Visiting professor at University of Pennsylvania and Johns Hopkins Medical School World-recognized expert in tissue physiology, especially in brain metabolism. He Published over 150 papers and patents. He has published over 170 papers in scientific journals and is the author of five patents. Prof. Mayevsky completed PhD from Weizmann Institute of Science, Rehovot, Israel.
BIXT is a Biotech. BIXT has a Patent covering 60+ virus applications for a non toxic carbohydrate based antivial, that cleared Covid19 in as little as 2 days, with no rebound. Cleared most of a Shingles skin outbreak as a cream.
The recent 10 Million dollars of zero dilution (not a loan, not a debt, no shares used) funding from the HEMEFoundation is for completing the work on the worlds first synthetic HEME Iron oxygen carrier.
https://hemefoundation.org/global-blood-shortage/
Seems to be convinced $BIXT has a massive future saving lives.
https://www.bioxytraninc.com/invest
https://www.bioxytraninc.com/press-releases/bioxytran-announces-preprint-of-shingles-case-study-showing-clearance-using-a-topical-galectin-3-antagonist
https://www.bioxytraninc.com/press-releases/bioxytran-launches-joint-venture-with-the-heme-foundation-for-development-of-universal-oxygen-carrier
https://assets-global.website-files.com/5cd9cf5f4183373f6b248799/63b59e37a80db77c70840b2a_Bioxytran%20Investor%207%20Jan%202022%20(NXPowerLite%20Copy).pdf
https://www.bioxytraninc.com/invest#press-releases
https://www.bioxytraninc.com/invest#presentation
https://www.otcmarkets.com/stock/BIXT/overview
https://www.bioxytraninc.com/resources#SCIENTIFIC-PUBLICATIONS
BIXT recorded presentation from 4 weeks ago.
Has anyone visited this company?, I try to visit three micros that I am in or looking to buy each year to try to get a feel for the possibilities of where the company will be over next 6-12 months, sometimes you can get great info by visiting
What kind of company? Why bullish?
I guess it's time to dip into my beer & pretzels stash and load up on Bioxytran again...
Here at #DDAmanda we track SS changes, and $BIXT hasn't had any since June.........And then it was only 2M, or 1%.......And that was the OS.
Last increase of the Float was back in May..
Z
$BIXT seems no one has noticed the dilution S-1 was withdrawn in a recent 8k filing, because they have non dilutive funding now, 10 million dollars of non dilutive funding for starters from the JV HEME Foundation, partnership to complete the BIXT synthetic HEME iron oxygen carrier that can reduce deaths, brain damage, heart and organ failure from blood clots and blood loss in emergencies:
PR is out folks. This should rally hard the rest of this year. $BIXT
10-30 Million dollar non dilutive, JV, staged funding is done.
12 Bagger upside to 2023 High at $1.25 likely.
Also the S-1 cash raise filing was withdrawn, and cancelled. No dilution. Tiny float 70% of the OS is insider founders owned
Did I mention the market cap is way under the $10 Million they just scored with no dilution to shareholders?
BIXT does not need money now. And BIXT is not a one trick horse.
What happens when the Heart or brain run out of Oxygen?
PR is out folks. https://www.globenewswire.com/en/news-release/2024/07/18/2915310/0/en/Bioxytran-Launches-Joint-Venture-with-the-Heme-Foundation-for-Development-of-Universal-Oxygen-Carrier.html
https://hemefoundation.org/
$BIXT Emerging Markets live about 1PM EST CEO and VP interview today
https://emerginggrowth.com/emerging-growth-conference-73/
GM Sir. and YES there is!!! $BIXT has gone for panhandling for 1 Million dollars, to scoring a 3 entity JV 10-30 Million dollar funding, NO DILUTION deal for one of other inventions they have
PR is out folks. This should rally hard the rest of this week. $BIXT
10-30 Million dollar non dilutive, JV, staged funding is done.
12 Bagger upside to 2023 High.
Also the S-1 cash raise filing was withdrawn, and cancelled.
BIXT does not need money now.
https://www.globenewswire.com/en/news-release/2024/07/18/2915310/0/en/Bioxytran-Launches-Joint-Venture-with-the-Heme-Foundation-for-Development-of-Universal-Oxygen-Carrier.html
Crazy good news. Fingers crossed this pumps to a $1
News tomorrow clarifying. $$$
Read my last post above.
10-30 Million dollar JV, non dilutive, solved the problem. It's all good, in fact it is awesome news. All of it.
Yes, an 8-K days ago, and an 8-K today, PR coming tomorrow and online live Emerging markets interview tomorrow.
$NDPD $BIXT Heme News
That post was from almost one year ago...Is there any article more recent that would clue us in on Bioxytran's current progress? Thanks!
Macchio is correct. From MDX website (notice the vague answers--tricky wording on several items on website??)
Q. WHAT IS THE REGULATORY STATUS OF THE DEVELOPED MEDICAL DEVICE?
A. MDX Life Sciences is capable to provide a FDA approved device that will monitor 4 physiological
parameters from tissues of patients in real time. The TMS will need a special approval by the FDA.
Where do you do your DD dude? The library of the Roman Empire or the Middle ages?|
More Hogwash and fairy tails just like you did on IFUS, before you got schooled and educated by me?
"MDX Viewer as an analytical method, which is an FDA approved device to measure tissue oxygenation. The device measures the consumption of oxygen molecules in tissues on a cellular level.
The output of the MDX Viewer is the Brain Metabolic Score BMS, which is a vital part of the approval process for Bioxytran’s acellular oxygen carrier (AOC) molecule called BXT-25. Bioxytran plans on using the BXT-25 in its clinical trials for ischemic stroke and Alzheimer’s disease patients as a way to replace hyperbaric oxygen treatment (HBOT).
Science behind the product:
Bioxytran has a significant subject matter expertise in the formulation of an oral form of a Galectin inhibitor. The company was able to capitalize on Dr Platt’s many years of research and recent peer reviewed articles on Galectins and COVID-19 to quickly complete the proof of concept phase. Dr Platt, who has a PhD in carbohydrate chemistry, was the first scientist to express the gene, which he named Galectin, 28 years ago.
We know that the N-terminal domain (NTD) of the coronavirus spike protein is similar from genus to genus. On the COVID-19 spike protein scientists have elucidated a galectin fold on the side of the spike that should have a binding affinity to sugar carbohydrates like ProLectin. Animal studies on influenza (needs reference) have demonstrated that inhibiting galectin-1 improves outcomes in lethal influenza models. Other animal’s models show that galectin inhibitors act as immune modulators in cancer and other diseases.
Our molecule is designed to stay in the blood and attach to the COVID-19 protein spikes. When the inhibitor binds to the spike it effectively tags the virus for elimination through the liver. Galectins are theorized to participate in the antiviral defense which starts at the initial recognition of the virus before it binds to the entry receptor all the way through the activation and amplification of the innate and adaptive responses of the immune system.
Galectins are adhesion molecules and allow neutrophils to stay prepositioned in the pulmonary capillaries for a quicker reaction in case of infection. They are also involved in the trafficking of macrophages responsible for the inflammatory cycle of the cytokine storm. Additionally, research in cancer and viruses has demonstrated that galectins form a plaque on CD-8 T-cells which inhibit the adaptive immune response. Therefore, our galectin antagonist should not only reduce the viral load of COVID-19, but also modulate the immune response by reducing the trafficking of macrophages thereby reducing the cytokine storm and returning the immune system to homeostasis. We also expect it to restore functionality to the adaptive immune system by reactivating anergic T-cells that were covered in galectin plaque.
If given early in the disease, we believe that our first drug candidate, galectin antagonist, will block viral entry and tag the virus for elimination through the liver. In theory the virus will be eliminated from the blood stream after a couple of treatments. At a later stage in the disease pathology, a more potent IV solution, ProLectin- I could restore adaptive immune function to help eradicate the virus from the body. In severe COVID-19 patients the drug, ProLectin-A, could reduce the trafficking of macrophages responsible for the cytokine storm and restore immune homeostasis. ProLectin-F is designed to treat organ damage after virus is eliminated from the system.
Galectin Antagonist is the first-in-class of inhibitors to cover a range of Galectins associated with viral replication adhesion and immune system blockage (not modulation). The N-terminal domain (NTD) of the coronavirus spike protein is similar from genus to genus. On the COVID-19 spike protein the Galectin fold on the side of the spike has a binding affinity to sugar carbohydrates like Galectin Antagonist.
Galectins are members of a family of proteins called lectins. These proteins interact with carbohydrate sugars located on the surface, in between cells, and on the Galectin fold of the spike protein. These interactions cause the cells to change behavior, including cell movement, multiplication, and other cellular functions. The interactions between lectins and their target carbohydrate sugars occur via a carbohydrate recognition domain (CRD), within the lectins. Galectins have a CRD that binds specifically to sugar molecules. They have a broad range of functions, including regulation of cell survival and adhesion, promotion of cell-to-cell interactions, growth of blood vessels, regulation of the immune response and inflammation. During viral infections Galectins are upregulated and downregulated based on the type of virus.
Bioxytran intends to develop and, through third party contracts, manufacture oxygen therapeutics. Our oxygen therapeutics are a new class of pharmaceuticals that are administered intravenously to transport oxygen to the body’s tissues. Currently there are four drug candidates to treat a stroke. Abciximab from Eli Lilly is a platelet aggregation inhibitor. Clinical trials show little advantage over placebos and could lead to dangerous side effects, including more bleeding in patients. Cerovive from AstraZeneca is a Nitrone-based neuro protectant currently in phase III clinical trials which shows no significant benefit over placebos with respect to changes in neurological impairment as measured by the national institute of health stroke scale. Candesartan, from AstraZeneca, is an angiotensin receptor blocker which was used to control blood pressure. Its efficacy in stroke patients still must be proven. Ancod from Knoll Pharmaceuticals is an anti-coagulant that acts by breaking down the fibrinogen. It increases the risk of hemorrhage similar to those associated with tPA. Using our issued patents and proprietary technology, we intend to develop and manufacture BXT-25 and similar drugs for applications including treatment of stroke conditions. Our patent position consists of 2 parts: a patent related to our co-polymer technology issued in 2009 by the United States Patent and Trademark Office expiring in February 2029 (method patent for producing modified pectins consisting of neutral sugar sequences ) and assigned to us outright by David Platt; various methods to stabilize a single hemoglobin molecule that are in the public domain; Dr. Platt did not receive any compensation from the Company in consideration of his assignment of the patent. Additionally, Bioxytran, Inc. has an exclusive license for an FDA approved technology monitoring NADH (OxySense), the control marker in the body’s conversion of Oxygen to Energy, or the energy generating chain. The technology provides a clinical end-point for measuring oxygen supply to the brain in real-time. OxySense, developed by MDX LifeSciences, Inc., provide us with a rapid, cost-effective and validated development of safe new molecules that address unmet medical needs in disease indications resulting from hypoxia. MDX LifeSciences has licensed a patent (Tissue Metabolic Score for Patient Monitoring) to Bioxytran for clinical monitoring of oxygen delivery through oxygen carriers.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |